How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma

doi:10.4254/wjh.v8.i35.1541

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7030)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

462

WORD

177

HTML

3231

Figures (1-1)

243

Tables (1-1)

246

Sum=4359

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1243

Download

1428

Sum=2671

Dec 18, 2016 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Dec 18, 2016; 8(35): 1541-1546
Published online Dec 18, 2016. doi: 10.4254/wjh.v8.i35.1541

Table 1 Parameters of post-progression survival for patients receiving sorafenib

Performance status

Child-Pugh class

BCLC class

CLIP score

Macroscopic venous invasion

AFP serum level

TTP on sorafenib

Pattern of progression

BCLC: Barcelona Clinic Liver Cancer staging classification; CLIP: Cancer of the Liver Italian Program; AFP: Alpha-fetoprotein; TTP: Time to progression.

Citation: Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol 2016; 8(35): 1541-1546
URL: https://www.wjgnet.com/1948-5182/full/v8/i35/1541.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i35.1541